Other than the statement about no change in eGFR over time, I think that the only new info is some baseline data for the CKD subgroup split by apabetalone vs. placebo. However, many baseline metrics are missing from this that were previously reported for the entire CKD group (not split by treatment). See 2018 poster compared to slide 16 from today.

https://www.resverlogix.com/upload/media_element/125/20402f6425eb/2018-05-02-era-edta-poster-2018-kidney-disease-subgroup.pdf

https://www.resverlogix.com/upload/media_element/213/24d969dcb90b/zadeh-eraedta-presentation---rvx-website-2020-06-08.pdf